Apoptosis Inhibition by the Human DEK Oncoprotein Involves Interference with p53 Functions
- 1 October 2006
- journal article
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 26 (20) , 7506-7519
- https://doi.org/10.1128/mcb.00430-06
Abstract
The DEK proto-oncogene has been associated with human carcinogenesis—either as a fusion with the CAN nucleoporin protein or when transcriptionally upregulated. Mechanisms of intracellular DEK functions, however, have remained relatively unexplored. We have recently demonstrated that DEK expression is induced by the high-risk human papillomavirus (HPV) E7 protein in a manner which is dependent upon retinoblastoma protein function and have implicated DEK in the inhibition of cellular senescence. Additionally, overexpression of DEK resulted in significant life span extension of primary human keratinocytes. In order to determine whether DEK expression is required for cellular proliferation and/or survival, we monitored cellular responses to the knockdown of DEK in cancer and primary cells. The results indicate that DEK expression protects both HPV-positive cancer and primary human cells from apoptotic cell death. Cell death in response to DEK depletion was accompanied by increased protein stability and transcriptional activity of the p53 tumor suppressor and consequent upregulation of known p53 target genes such as p21CIP and Bax. Consistent with a possible role for p53 in DEK-mediated cell death inhibition, the p53-negative human osteosarcoma cell line SAOS-2 was resistant to the knockdown of DEK. Finally, expression of a dominant negative p53 miniprotein inhibited DEK RNA interference-induced p53 transcriptional induction, as well as cell death, thus directly implicating p53 activation in the observed apoptotic phenotype. These findings suggest a novel role for DEK in cellular survival, involving the destabilization of p53 in a manner which is likely to contribute to human carcinogenesis.Keywords
This publication has 69 references indexed in Scilit:
- Intron Removal Requires Proofreading of U2AF/3' Splice Site Recognition by DEKScience, 2006
- DEK Expression is Controlled by E2F and Deregulated in Diverse Tumor TypeCell Cycle, 2006
- Cancer genes and the pathways they controlNature Medicine, 2004
- Defining a 0.5-Mb Region of Genomic Gain on Chromosome 6p22 in Bladder Cancer by Quantitative-Multiplex Polymerase Chain ReactionThe American Journal of Pathology, 2004
- Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entryNature, 2003
- YY1 and NF-Y binding sites regulate the transcriptional activity of the dek and dek-can promoterOncogene, 2002
- Protein Interactions Targeting the Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus to Cell ChromosomesJournal of Virology, 2002
- Live or let die: the cell's response to p53Nature Reviews Cancer, 2002
- The identification of novel therapeutic targets for the treatment of malignant brain tumorsCancer Letters, 2000
- Autoantibodies to DEK oncoprotein in a patient with systemic lupus erythematosus and sarcoidosisArthritis & Rheumatism, 1998